Speaker Profile

Ph.D., VP R&D, MedGenome
Biography

As the Head of R&D at MedGenome, my focus is to leverage next generation sequencing technologies to investigate diseases and develop solutions for efficient translation of therapies in the clinic. In the area cancer immunotherapy, I have developed a genomics-based integrated platform OncoPept, which combines four separate solutions: A high throughput cancer vaccine discovery and validation solution; tumor microenvironment analysis; TCR repertoire analysis; and the prediction of immune-related toxicity associated with checkpoint inhibitors. This platform is used by pharma and biotech companies in their preclinical and clinical studies. For over 15 years I have been working in the area of high throughput genomics and proteomics-based drug discovery research first in a mid-size genomics company CuraGen Corporation, followed by at Genentech, a large pharmaceutical company. I have done my graduate studies in Biochemistry followed by post-doctoral work in yeast genetics and B-cell biology.

Immunotherapy Showcase: MedGenome
MedGenome accelerates biomarker discovery leveraging population genetics and NGS-based solutions.

Overcoming Challenges in Personalized Cancer Vaccine Design
Cancer vaccine therapy is a promising tool to fight cancer. The goal of cancer vaccines is to produce strong anti-tumor response against tumor-specific neoantigens. The presentation will discuss challenges in designing effective cancer vaccines and strategies to overcome them.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!